Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - trizivir
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp2dca39e00c4bb300a2d0bc7e52b63f20
identifier: http://ema.europa.eu/identifier
/EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-2dca39e00c4bb300a2d0bc7e52b63f20
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - trizivir
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Trizivir is used to treat HIV (human immunodeficiency virus) infection in adults.
Trizivir contains three active ingredients that are used to treat HIV infection: abacavir, lamivudine and zidovudine. All of these belong to a group of anti-retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Trizivir helps to control your condition. Trizivir does not cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. This helps your body to increase the CD4 cell count in your blood. CD4 cells are a type of white blood cell that are important in helping your body to fight infection.
Not everyone responds to treatment with Trizivir in the same way. Your doctor will monitor the effectiveness of your treatment.
Do not take Trizivir:
Take special care with Trizivir Some people taking Trizivir are more at risk of serious side effects. You need to be aware of the extra risks:
Abacavir hypersensitivity reactions Even patients who don t have the HLA-B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction).Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.
Risk of cardiovascular events It cannot be excluded that abacavir may increase the risk of having cardiovascular events. Tell your doctor if you have cardiovascular problems, if you smoke, or have other illnesses that may increase your risk of cardiovascular diseases such as high blood pressure, or diabetes. Do not stop taking Trizivir unless your doctor advises you to do so.
Look out for important symptoms Some people taking Trizivir develop other conditions, which can be serious. You need to know about important signs and symptoms to look out for while you are taking Trizivir. Read the information Other possible side effects of Trizivir in Section 4 of this leaflet.
Other medicines and Trizivir Tell your doctor or pharmacist if you are taking any other medicines, or if you have taken any recently, including herbal medicines or other medicines you bought without a prescription.
Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Trizivir.
These medicines should not be used with Trizivir:
Some medicines can make it more likely that you will have side effects, or make side effects worse
These include:
Some medicines interact with Trizivir These include:
clarithromycin, an antibiotic If you are taking clarithromycin, take your dose at least 2 hours before or after you take your Trizivir.
phenytoin, for treating epilepsy Tell your doctor if you are taking phenytoin. Your doctor may need to monitor you while you are taking Trizivir
medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly. Tell your doctor or pharmacist if you are taking any of these.
riociguat, for treating high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. Your doctor may need to reduce your riociguat dose, as abacavir may increase riociguat blood levels.
Methadone and Trizivir Abacavir increases the rate at which methadone is removed from the body. If you are taking methadone, you will be checked for any withdrawal symptoms. Your methadone dose may need to be changed.
Pregnancy If you are pregnant, if you become pregnant or if you are planning to become pregnant, talk to your doctor about the risks and benefits to you and your baby of taking Trizivir during your pregnancy.
Trizivir and similar medicines may cause side effects in unborn babies.
If you have taken Trizivir during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Breast-feeding Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Trizivir can also pass into your breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
Driving and using machines Trizivir can make you dizzy and have other side effects that make you less alert. Don t drive or operate machines unless you re feeling well.
Important information about some of the other ingredients of Trizivir tablets. This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially sodium-free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Keep in touch with your doctor, and do not stop taking Trizivir without your doctor s advice.
How much to take The usual dose of Trizivir for adults is one tablet twice a day.
Take the tablets at regular times, leaving approximately 12 hours between each tablet.
Swallow the tablets whole, with some water. Trizivir can be taken with or without food.
If you take more Trizivir than you should If you accidentally take too much Trizivir, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advice.
If you forget to take Trizivir If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before.
Do not take a double dose to make up for a forgotten dose.
It is important to take Trizivir regularly, because if you take it at irregular intervals it may not continue to work against the HIV infection, and you may be more likely to have a hypersensitivity reaction.
If you have stopped taking Trizivir If you have stopped taking Trizivir for any reason especially because you think you are having side effects, or because you have other illness: Talk to your doctor before you start taking it again. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been related, you will be told never again to take Trizivir, or any other medicine containing abacavir (Kivexa,Triumeq or Ziagen). It is important that you follow this advice.
If your doctor advises that you can start taking Trizivir again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
Treatment with Trizivir often causes a loss of fat from legs, arms and face (lipoatrophy). This loss of body fat has been shown to be not fully reversible after discontinuation of zidovudine. Your doctor should monitor for signs of lipoatrophy. Tell your doctor if you notice any loss of fat from your legs, arms, and face. When these signs occur, Trizivir should be stopped and your HIV treatment changed.
Like all medicines, this medicine can cause side effects, although not everyone gets them.
When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Trizivir or other medicines you are taking, or an effect of the HIV infection itself. So it is very important to talk to your doctor about any changes in your health.
Even patients who don t have the HLA-B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction), described in this leaflet in the panel headed Hypersensitivity reactions . It is very important that you read and understand the information about this serious reaction.
As well as the side effects listed below for Trizivir, other conditions can develop during treatment.
It is important to read the information on the other side of this leaflet under Other possible side effects of Trizivir .
Hypersensitivity reactions Trizivir contains abacavir (which is also an active substance in Kivexa, Triumeq and Ziagen). Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction. These hypersensitivity reactions have been seen more frequently in people taking medicines that contain abacavir.
Who gets these reactions? Anyone taking Trizivir could develop a hypersensitivity reaction to abacavir, which could be life threatening if they continue to take Trizivir. You are more likely to develop such a reaction if you have a gene called HLA-B*5701 (but you can get a reaction even if you do not have this gene). You should have been tested for this gene before Trizivir was prescribed for you. If you know you have this gene, tell your doctor before you take Trizivir.
About 3 to 4 in every 100 patients treated with abacavir in a clinical trial who did not have the HLA- B*5701 gene developed a hypersensitivity reaction.
What are the symptoms? The most common symptoms are:
When do these reactions happen? Hypersensitivity reactions can start at any time during treatment with Trizivir, but are more likely during the first 6 weeks of treatment.
Contact your doctor immediately: 1 if you get a skin rash, OR 2 if you get symptoms from at least 2 of the following groups:
fever
shortness of breath, sore throat or cough
nausea or vomiting, diarrhoea or abdominal pain
severe tiredness or achiness, or generally feeling ill
Your doctor may advise you to stop taking Trizivir.
If you have stopped taking Trizivir If you have stopped taking Trizivir because of a hypersensitivity reaction, you must NEVER AGAIN take Trizivir, or any other medicine containing abacavir (Kivexa, Triumeq or Ziagen). If you do, within hours, your blood pressure could fall dangerously low, which could result in death.
If you have stopped taking Trizivir for any reason especially because you think you are having side effects, or because you have other illness: Talk to your doctor before you start again. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been, you will then be told never again to take Trizivir, or any other medicine containing abacavir (Kivexa, Triumeq or Ziagen). It is important that you follow this advice.
Occasionally, hypersensitivity reactions have developed in people who start taking abacavir containing products again, but who had only one symptom on the Alert Card before they stopped taking it.
Very rarely, patients who have taken medicines containing abacavir in the past without any symptoms of hypersensitivity have developed a hypersensitivity reaction when they start taking these medicines again.
If your doctor advises that you can start taking Trizivir again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.
If you are hypersensitive to Trizivir, return all your unused Trizivir tablets for safe disposal. Ask your doctor or pharmacist for advice. The Trizivir pack includes an Alert Card, to remind you and medical staff about hypersensitivity reactions. Detach this card and keep it with you at all times.
Very common side effects These may affect more than 1 in 10 people:
Common side effects These may affect up to 1 in 10 people:
hypersensitivity reaction
being sick (vomiting)
diarrhoea
stomach pains
loss of appetite
feeling dizzy
tiredness, lack of energy
fever (high temperature)
general feeling of being unwell
difficulty in sleeping (insomnia)
muscle pain and discomfort
joint pain
cough
irritated or runny nose
skin rash
hair loss Common side effects that may show up in blood tests are:
a low red blood cell count (anaemia) or low white blood cell count (neutropenia or leukopenia)
an increase in the level of liver enzymes
an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow
Uncommon side effects These may affect up to 1 in 100 people:
Rare side effects These may affect up to 1 in 1000 people:
Very rare side effects These may affect up to 1 in 10,000 people:
a failure of the bone marrow to produce new red or white blood cells (aplastic anaemia)
If you get side effects
Tell your doctor or pharmacist if any of the side effects gets severe or troublesome, or if you notice any side effects not listed in this leaflet.
Other possible side effects of Trizivir Trizivir may cause other conditions to develop during HIV treatment.
Symptoms of infection and inflammation
Old infections may flare up People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body s immune system becoming stronger, so that the body starts to fight these infections. Symptoms usually include fever, plus some of the following:
In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders). The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:
If you get any symptoms of infection while you re taking Trizivir: Tell your doctor immediately. Do not take other medicines for the infection without your doctor s advice.
Lactic acidosis is a rare but serious side effect Some people taking Trizivir develop a condition called lactic acidosis, together with an enlarged liver.
Lactic acidosis is caused by a build-up of lactic acid in the body. It is rare; if it happens, it usually develops after a few months of treatment. It can be life-threatening, causing failure of internal organs.
Lactic acidosis is more likely to develop in people who have liver disease, or in obese (very overweight) people, especially women. Signs of lactic acidosis include:
You may have problems with your bones Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tissue die because of reduced blood supply to the bone. People may be more likely to get this condition:
Other effects may show up in blood tests Trizivir can also cause:
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not take this medicine after the expiry date shown on the carton. The expiry date refers to the last day of that month.
Do not store above 30 C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures help protect the environment.
What Trizivir contains The active substances in each Trizivir film-coated tablet are 300 mg of abacavir (as sulfate), 150 mg lamivudine and 300 mg zidovudine.
The other ingredients are microcrystalline cellulose, sodium starch glycollate and magnesium stearate in the core of the tablet. The tablet coating contains hypromellose, titanium dioxide, polyethylene glycol, indigo carmine aluminium lake, iron oxide yellow.
What Trizivir looks like and contents of the pack Trizivir film-coated tablets are engraved with GX LL1 on one side. They are blue/green and capsule- shaped and are provided in blister packs containing 60 tablets or bottles containing 60 tablets with child-resistant tops.
Marketing Authorisation Holder ViiV Healthcare BV Van Asch van Wijckstraat 55H
3811 LP Amersfoort Netherlands
Manufacturer Delpharm Pozna Sp ka Akcyjna, ul. Grunwaldzka 189 , 60-322 Poznan, Poland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien ViiV Healthcare srl/bv
T l/Tel: + 32 (0) 10 85 65 Lietuva ViiV Healthcare BV Tel: + 370 80000
ViiV Healthcare BV Te .: + 359 80018Luxembourg/Luxemburg ViiV Healthcare srl/bv
Belgique/Belgien T l/Tel: + 32 (0) 10 85 65 esk republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 cz.info@gsk.com
Magyarorsz g ViiV Healthcare BV Tel.: + 36 80088Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 dk-info@gsk.com
Malta ViiV Healthcare BV Tel: + 356 80065Deutschland ViiV Healthcare GmbH
Tel.: + 49 (0)89 203 0038-viiv.med.info@viivhealthcare.com
Nederland ViiV Healthcare BV
Tel: + 31 (0) 33 2081Eesti ViiV Healthcare BV Tel: + 372 8002Norge GlaxoSmithKline AS Tlf: + 47 22 70 20
GlaxoSmithKline A.E.B.E. : + 30 210 68 82 sterreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com
Espa a Laboratorios ViiV Healthcare, S.L.
Tel: +34 900 923 es-ci@viivhealthcare.com
Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9France ViiV Healthcare SAS
T l.: + 33 (0)1 39 17 6Infomed@viivhealthcare.com
Hrvatska ViiV Healthcare BV Tel: + 385 800787Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA
Tel: + 351 21 094 08 viiv.fi.pt@viivhealthcare.com
Rom nia ViiV Healthcare BV
Tel: + 40800672Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955Slovenija ViiV Healthcare BV Tel: + 386 80688 sland Vistor hf.
S mi: +354 535 7Slovensk republika ViiV Healthcare BV Tel: + 421 800500Italia ViiV Healthcare S.r.l
Tel: + 39 (0)45 7741Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30
ViiV Healthcare BV : + 357 80070Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 info.produkt@gsk.com
Latvija ViiV Healthcare BV Tel: + 371 80205United Kingdom (Northern Ireland) ViiV Healthcare BV
Tel: + 44 (0)800 221customercontactuk@gsk.com
This leaflet was last revised in {MM/YYYY}
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-2dca39e00c4bb300a2d0bc7e52b63f20
Resource Composition:
Generated Narrative: Composition composition-en-2dca39e00c4bb300a2d0bc7e52b63f20
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - trizivir
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp2dca39e00c4bb300a2d0bc7e52b63f20
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp2dca39e00c4bb300a2d0bc7e52b63f20
identifier:
http://ema.europa.eu/identifier
/EU/1/00/156/002 – opaque white PCTFE/PVC-Al Blister pack (60 Tablets)type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en